Skip to main content
. Author manuscript; available in PMC: 2012 Sep 3.
Published in final edited form as: Clin Cancer Res. 2010 Aug 27;16(24):6159–6168. doi: 10.1158/1078-0432.CCR-10-1027

Figure 3. Raw RAD51 count shows a biphasic relationship with proliferation in 24 hour post chemotherapy biopsies.

Figure 3

A. Plot of raw RAD51 counts (x axis, percentage of tumour cells that have RAD51 foci) against proliferative fraction assessed on same section (y axis, percentage of tumour cells with nuclear geminin expression) in core biopsies from 57 tumours taken at 24 hours post chemotherapy. In tumours with a raw RAD51 count >2% there is a positive correlation between RAD51 count and proliferation (ρ=0.67, 95% CI 0.45-0.82, p<0.0001, Spearman's correlation coefficient), but not in tumours with raw RAD51 count <2% (r=−0.21, p=NS). Open circles indicate tumours subsequently assessed as having a low RAD51 score (Figure 4).

B. Assessment of the relationship between geminin positive and RAD51 positive cells. For each tumour the percentage of geminin positive cells that had RAD51 foci, and the percentage geminin negative cells that had RAD51 foci was assessed. Displayed are the results from all 57 tumours, with the percentage of geminin positive cancer cells that have RAD51 foci (median 40%, left), versus the percentage of geminin negative cancer cells that have RAD51 foci (median 0%, right). RAD51 foci are almost exclusively expressed in geminin positive cells (p<0.0001 Mann-Whitney U Test).